[go: up one dir, main page]

HK1002708B - Method of introducing a 1,2 double bond into azasteroids - Google Patents

Method of introducing a 1,2 double bond into azasteroids Download PDF

Info

Publication number
HK1002708B
HK1002708B HK98101899.3A HK98101899A HK1002708B HK 1002708 B HK1002708 B HK 1002708B HK 98101899 A HK98101899 A HK 98101899A HK 1002708 B HK1002708 B HK 1002708B
Authority
HK
Hong Kong
Prior art keywords
compound
formula
butyl
straight
hydrogen
Prior art date
Application number
HK98101899.3A
Other languages
German (de)
French (fr)
Chinese (zh)
Other versions
HK1002708A1 (en
Inventor
O. King Anthony
M. Weinstock Leonard
R. Anderson Kevin
F. Shuman Richard
Original Assignee
Merck & Co., Inc.
Filing date
Publication date
Priority claimed from US07/434,663 external-priority patent/US5021575A/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of HK1002708B publication Critical patent/HK1002708B/en
Publication of HK1002708A1 publication Critical patent/HK1002708A1/en

Links

Description

BACKGROUND OF THE INVENTION
This invention is concerned with a process for dehydrogenating azasteroids, in particular 17β substituted 3-oxo-4-azasteroids, to provide the corresponding compound having a double bond at its 1,2 position.
Heretofore, azasteroids have been dehydrogenated to introduce a 1,2 double bond by means of benzene seleninic anhydride oxidation in which the saturated compound was heated with the benzene seleninic anhydride in refluxing chlorobenzene. Back, T.G., J. Org. Chem., 46, 1442 (1981); Rasmussen et al., J. Med. Chem. 29, 2298 (1986), Dehydrogenation of azasteroids utilizing benzeneseleninic acid or benzene seleninic anhydride to form the corresponding Δ¹ compound is also discussed in Back, T.G., J.C.S. Chem. Comm., 278-279 (1978). Additionally, sulfoxide elimination has been a process used to accomplish the dehydrogenation. See U.S. Patent No. 4,377,584, 4,220,775 and EP-A-155,096. However these reactions have been found to give poor yields, with a high degree of impurities and one requires the use of a selenium catalyst which is very expensive and is quite toxic.
It has also been known to dehydrogenate a 3-oxo-4-azalactam by a complicated 5-step process which involves a sulfenate intermediate. See Magnus et al., J. Am. Chem. Soc., 108, 221-227 (1986). More recently, a dehydrogenation process involving a silylation-mediated DDQ oxidation of 4-aza-3-ketosteroids to the corresponding Δ¹-lactams has been developed. See Bhattacharya et al., J. Am. Chem. Soc., 110, 3318 (1988), and EP-A-298,652.
The process of the present invention provides a method for introducing a 1,2 double bond into 17β-substituted 3-oxo-4-azasteroids via a four step process utilizing oxalyl chloride. The present invention thus provides an alternative process for the 1(2)-dehydrogenation of 3-keto-4-aza-steroids which avoids the use of toxic selenium catalysts.
SUMMARY OF THE INVENTION
The present invention provides a method for introducing a 1,2 double bond into a compound of the formula: wherein R is
  • (i) a straight or branched chain alkyl group having 1 to 12 carbons;
  • (ii) a straight or branched chain alkyl group having 1 to 12 carbons in which a hydrogen is substituted with a hydroxy, carboxylic acid or an alkyl ester having 1 to 4 carbons;
  • (iii) a cycloalkyl group having 4 to 8 carbons;
  • (iv) phenyl;
  • (v) OR⁴ where R⁴ is hydrogen or alkali metal, a C₁₋₁₈ straight or branched chain alkyl group or benzyl;
  • (vi) NR²R³, where R² and R³ are each independently selected from hydrogen, C₁₋₁₂ straight or branched chain alkyl, C₁₋₁₂ straight or branched chain alkyl having a hydrogen substituted with a hydroxy, carboxoylic acid or C₁₋₄ alkyl ester, C₃₋₁₀ cycloalkyl, phenyl, or R² and R³ taken together with the nitrogen to which they are attached represent a 5-6 member saturated ring comprising up to one other heteroatom selected from oxygen and nitrogen; and
R¹ is hydrogen; by
  • (a) reacting the compound of formula I with oxalyl chloride to produce a compound of the formula:
  • (b) reacting the compound of formula III with bromine to produce a compound of the formula:
  • (c) reacting the compound of formula VI with ethylenediamine, an N,N'-dialkylethylenediamine or 2-(methylamino)ethanol to produce a compound of the formula:
  • (d) reacting the compound of formula IX with potassium t-butoxide, 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), tetrabutylammonium fluoride or N,N,N',N'-tetramethylethylenediamine to introduce a double bond at the 1,2 position of the compound of formula I.
The 4-azasteroid compounds prepared by the processes of the present invention are testosterone-5α-reductase inhibitors useful for treating the hyperandrogenic conditions of acne vulgaris, seborrhea, female hirsutism, androgenic alopecia including male pattern alopecia, prostatic carcinoma and benign prostatic hypertrophy by topical or systemic administration.
The schematic flow diagram which follows shows the processes of the present invention.    Since all intermediates leading to products such as 2-bromo-5α-azasteriods are water sensitive, water should be vigorously excluded from the reaction. The reaction of oxalyl chloride with 5α-azasteroids in methylene chloride in the presence of an amine base such as diisopropylethylamine or pyridine gives vinylidenyloxazolidinediones. Other solvents such as chloroform and carbon tetrachloride can also be utilized. On bromination, vinylidinyloxazolidinediones are converted to dibromooxazolidinediones which are unstable and dehydrobrominate spontaneously in solution on warming to give bromovinylidinyloxazolidinediones. Reaction of ethylenediamine, N, N¹-dialkylethylenediamines or 2-(methylamino)ethanol with bromovinylidineoxazolidinediones gives 2-bromo-5α-azasteroids as chemically stable and easily isolable products.
The dehydrobromination of 2-bromo-5α-azasteroids can be effected using potassium t-butoxide, DBN, DBU, tetrabutylammonium fluoride, and N, N, N¹,N¹-tetramethylethylenediamine in THF, DMF and DMSO, but the yields of ¹Δ-5α-azasteroids vary substantially depending on starting 2-bromo-5α-azasteroids, dehydrobrominating agents, and solvents used. The best results were obtained using 2-bromo-5α-azaamide with potassium t-butoxide in DMF. The experimental procedure for this latter steroid is described below. The overall yield was 60%.
The following examples should be considered as not limiting the invention and will serve to illustrate the manner in which the present invention is accomplished. All temperatures are in °C.
EXAMPLE 1 Oxalylation/Bromination/De-Oxalylation
A 500ml three-neck round bottom flask equipped with a stirrer, a thermometer, a nitrogen inlet and a distillation condenser was charged with 17β-(N-tert-butylcarbamoyl)-4-aza-5α-androstan-3-one (compound I, R = -NH-tert-butyl) (10 g., 26.7 mmol), pyridine (26.7 ml) and methylene chloride (300 ml). The methylene chloride solution was distilled under atmospheric pressure until 100 ml of methylene chloride was collected. The reaction mixture was cooled to -70°C and oxalyl chloride (2.56 ml, 29.4 mmol) was added dropwise over 10 min.
The mixture was warmed to 0°C and aged at this temperature until the reaction was complete and no starting material was observed (1 1/2 to 3 hrs.).
HPLC
Column: Dupont Zorbax C-8, 25 cm x 4.6 mm
Solvent: 60% CH₃CN - 40% H₂O (0.1% H₃PO₄)
Flow: 1.5 ml/min
Wavelength: 210 nm
Detector: Kratos Spectroflow 757, AVFS = 0.02
RT: Compound I, R = -NH-tert-butyl 4.6 min
Vinylidenyloxazolidinedione Amide (III, R = -NH-tert-butyl) 9.1/min
3-Hydroxyoxazolidinedione Amide (IV, R = -NH-tert-butyl) 4.9 min.
Epsilon-Caprolactam (0.226 g, 2 mmol) was added and the reaction further aged at 0°C for 1/2 hour.
The mixture was then cooled to -70°C and neat bromine (4.48 g, 28.0 mmol) was added. The reaction was aged for 15 minutes and then sampled and checked by HPLC to ensure that all vinylidinyloxazolidinedione amide (III, R = -NH-tert-butyl) had been consumed. More bromine could be added in small portions if necessary to complete the bromination reaction.
HPLC
Same conditions as above.
RT:
2-Bromo-3-hydroxyoxazolidinedione amide (VII, R = -NH-tert-butyl) 6.4 min, 6.7 min. 2-Bromovinylidenyloxazolidinedione amide (VI, R = -NH-tert-butyl) 13.3 min.
The reaction mixture was warmed to 0°C and aged (18-20 hrs) until all of the 2,3-dibromo-oxazolidinedione amide (V, R = -NH-tert-butyl) had been converted to bromovinylidenyloxazolidinedione amide (VI, R = -NH-tert-butyl). After cooling the mixture back to -65°C, 2-(methylamino)ethanol (9.02 g, 120.2 mmol) was added while maintaining the reaction temperature below -60°C.
The reaction was checked for the complete disappearance of the starting material by HPLC.
HPLC
Same conditions as reported above
RT:
2-Bromovinylidenyloxazolidinedione amide (VI, R = -NH-tert-butyl) 13.3 min.
Compound IX, R = -NH-tert-butyl 4.7 min & 5.0 min.
More 2-(methylamino)ethanol could be added in small portions (0.2 g) if the disappearance of bromovinylidineoxazolidinedione amide (VI, R = -NH-tert-butyl) was not complete.
The mixture was warmed to room temperature and aged until the aminoethanol intermediate adducts had been converted to 2-bromo-5α-azaamide (IX, R = -NH-tert-butyl) (2 to 3 hours).
The solution was cooled to 0°C and 200 ml of cold 2N HCL solution was added slowly while maintaining the temperature at ≦5°C. After the addition the two layers were thoroughly mixed and separated. The organic layer was washed again with 2N HCL (200 ml) followed by 10% brine (2x200 ml). To the methylene choloride solution was added acetonitrile (100 ml) and the methylene chloride was removed in vacuo at ≦40°C while maintaining the liquid volume at ∼35 ml by addition of acetonitrile.
When no more methylene chloride was detected in the distillate, the volume was further reduced to 35 ml of acetonitrile and the mixture was cooled to 0°C. Water (105 ml) was added slowly over 15 min. After aging for 1 1/2 hours at 0°C, the solid was collected by filtration and the filter cake washed with water (50 ml). The filter cake was suction dried to a free flowing solid and then further dried at 60°C in vacuo overnight (14 to 18 hours). The yield of Compound IX, R = -NH-tert-butyl, was 10.80 g, 85.1% corrected for 95.4 wt.% HPLC purity.
Dehydrobromination
In a 250 ml three-neck flask equipped with a stirrer, an internal thermometer, and a nitrogen inlet was charged potassium t-butoxide (6.15 g, 54.8 mmol) and 25 ml of dry DMF. After the potassium t-butoxide was completely dissolved, the mixture was cooled to 0°C and a solution of 2-bromo-5α-azaamide (IX, R = -NH-tert-butyl) (4.00 g, 8.8 mmol) in DMF (12 ml) was added dropwise while maintaining the temperature at 0°C.
After the addition was complete, the reaction was aged for an additional 10 min. and was then quenched by the dropwise addition of acetic acid (5.2 ml, 90 mmol) while keeping the temperature below 5°C. To the stirred solution was slowly added 200 ml of saturated sodium chloride. The suspension was stirred at 0°C for 4 hours and the solid was isolated by filtration and washed with 200 ml of distilled water. The crude product was dried overnight in vacuo at 70°C under a gentle nitrogen purge. The yield was 3.29 g, 80.2% corrected for 78.8% purity.
The crude 17β-(N-tert-butylcarbamoyl)-4-aza-5α-androst-1-en-3-one (hereinafter referred to as MK906) was dissolved in isopropyl acetate (100 ml) with heating and the volume reduced to 15 ml by distillation under reduced pressure. The suspension was stirred overnight at 0°C. The solid was isolated by filtration and dried in the vacuum oven at 70°C. The yield was 2.16 g, 64.6% corrected for 95.4% purity.
The above solid was again dissolved in 10 ml of acetic acid and 100 ml of water was added slowly. The product gradually crystallized out of solution. The mixture was aged at r.t. for 10 hours with agitation. After filtration and drying at 70°C in vacus, 1.97 g of white crystalline MK906 was obtained. The overall yield for the two steps was 60.2%, corrected for 98.0 wt. % purity.
HPLC
Same conditions as reported previously.
RT: MK906 4.25 min.

Claims (5)

  1. A method of introducing a double bond at the 1,2 position of a compound having the formula: wherein R is
    (i) a straight or branched chain alkyl group having 1 to 12 carbons;
    (ii) a straight or branched chain alkyl group having 1 to 12 carbons in which a hydrogen is substituted with a hydroxy, carboxylic acid or an alkyl ester having 1 to 4 carbons;
    (iii) a cycloalkyl group having 3 to 6 carbons;
    (iv) phenyl;
    (v) OR⁴ where R⁴ is hydrogen or alkali metal, a C₁₋₁₈ straight or branched chain alkyl group or benzyl;
    (vi) NR²R³, where R² and R³ are each independently selected from hydrogen, C₁₋₁₂ straight or branched chain alkyl, C₁₋₁₂ straight or branched chain alkyl having a hydrogen substituted with a hydroxy, carboxylic acid or C₁₋₄ alkyl ester, C₃₋₁₀ cycloalkyl, phenyl, or R² and R³ taken together with the nitrogen to which they are attached represent a 5-6 member saturated ring comprising up to one other heteroatom selected from oxygen and nitrogen;and
    R¹ is hydrogen; which comprises the steps of:
    (a) reacting the compound of formula I with oxalyl chloride to produce a compound of the formula:
    (b) reacting the compound of formula III with bromine to produce a compound of the formula:
    (c) reacting the compound of formula VI with ethylenediamine, an N,N'-dialkylethylenediamine or 2-(methylamino)ethanol to produce a compound of the formula:
    (d) reacting the compound of formula IX with potassium t-butoxide, 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), tetrabutylammonium fluoride or N,N,N',N'-tetramethylethylenediamine to introduce a double bond at the 1,2 position of the compound of formula I.
  2. The method of Claim 1 wherein R is NH-tert-butyl, iso-butyl, sec-butyl or phenyl.
  3. The method of Claim 2 wherein R is NH-tert-butyl.
  4. A method as claimed in any one of the preceding claims wherein, in step (c), the compound of formula VI is reacted with 2-(methylamino)ethanol.
  5. A method as claimed in any one of the preceding claims wherein, in step (d), the compound of formula IX is reacted with potassium t-butoxide.
HK98101899A 1989-11-13 1998-03-09 Method of introducing a 1,2 double bond into azasteroids HK1002708A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/434,663 US5021575A (en) 1989-11-13 1989-11-13 Method for introducing a 1,2 double bond into azasteroids

Publications (2)

Publication Number Publication Date
HK1002708B true HK1002708B (en) 1998-09-11
HK1002708A1 HK1002708A1 (en) 1998-09-11

Family

ID=23725148

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98101899A HK1002708A1 (en) 1989-11-13 1998-03-09 Method of introducing a 1,2 double bond into azasteroids

Country Status (8)

Country Link
US (1) US5021575A (en)
EP (2) EP0655459B1 (en)
JP (1) JPH0651718B2 (en)
CA (1) CA2029859C (en)
CY (2) CY2079B1 (en)
DE (2) DE69022540T2 (en)
HK (1) HK1002708A1 (en)
LV (1) LV12572B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US5120847A (en) * 1990-08-27 1992-06-09 Merck & Co., Inc. Process for iodinating or brominating the α-methylenic carbon of a secondary amide
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
CA2084799C (en) * 1991-12-17 2003-01-28 Glenn J. Gormley Method of prevention of prostatic carcinoma with 17 beta-n-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1 -en-3-ones
EP0547687A1 (en) * 1991-12-18 1993-06-23 Merck & Co. Inc. 17B-N-Substituted adamantyl/norbonanyl carbamoyl-4-aza-5a-and-rost-1-en-3-ones and androstan-3 ones
DE69225244T2 (en) * 1991-12-20 1998-09-24 Glaxo Wellcome Inc INHIBITORS OF TESTOSTERONE-5-ALPHA REDUCTASE.
US5302589A (en) * 1992-08-07 1994-04-12 Glaxo, Inc. Heterocyclic inhibitors of 5-α-testosterone reductase
US5468860A (en) * 1992-11-19 1995-11-21 Merck & Co., Inc. New finasteride processes
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US6001844A (en) 1995-09-15 1999-12-14 Merck & Co., Inc. 4-Azasteroids for treatment of hyperandrogenic conditions
US6365597B1 (en) 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
AUPO533497A0 (en) 1997-02-21 1997-03-20 Frontier Tower Pty Ltd Self-adhesive decorative devices
US6187925B1 (en) 1997-12-23 2001-02-13 Merck & Co., Inc. Intermediates and process for the synthesis of azasteroids
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
SK2732003A3 (en) * 2000-09-07 2004-01-08 Reddys Lab Ltd Dr Novel polymorphic form of 17-beta-(N-ter.butyl carbamoyl)-4-aza- 5-alpha-androst-1-en-3-one and a process for preparing it
CN1468254A (en) 2000-09-07 2004-01-14 雷迪实验室有限公司 Novel polymorphic forms of 17-beta- (N-tert-butylcarbamoyl) -4-aza-5-alpha-androst-1-en-3-one and process for their preparation
WO2002020553A1 (en) * 2000-09-07 2002-03-14 Dr. Reddy's Laboratories Ltd. NOVEL POLYMORPHIC FORM OF 17-β-(N-TER.BUTYL CARBAMOYL)-4-AZA-5-α-ANDROST-1-EN-3-ONE AND A PROCESS FOR PREPARING IT
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
ES2185503B1 (en) * 2001-09-29 2004-08-01 Ragactives, S.L. PROCEDURE FOR OBTAINING 17BETA- (REPLACED) -3-OXOALFA1,2-4-AZAESTEROIDS AND INTERMEDIATES.
HU227117B1 (en) 2002-05-10 2010-07-28 Richter Gedeon Nyrt Process for dehydrogenation of aza-androstane compounds
KR100872722B1 (en) * 2002-06-28 2008-12-05 주식회사 중외제약 Method of preparing finasteride
WO2004007523A1 (en) 2002-07-16 2004-01-22 Siegfried Generics International Ag Method for introducing a 1,2 double bond into 3-oxo-4-azasteroid compounds
ES2206065B1 (en) 2002-10-31 2005-08-16 Ragactives, S.L. PROCEDURE FOR OBTAINING THE POLYMORPHIC FORM I OF FINASTERIDA.
KR100508019B1 (en) 2003-07-19 2005-08-17 한미약품 주식회사 Method for the preparation of highly pure 1-androstene derivatives
ATE399756T1 (en) * 2003-07-21 2008-07-15 Siegfried Generics Int Ag METHOD FOR PRODUCING ALPHA, BETA-UNSATURATED AMI D COMPOUNDS
WO2005066196A1 (en) * 2003-12-30 2005-07-21 Ranbaxy Laboratories Limited Amorphous form of finasteride and processes for its preparation
US7531658B2 (en) * 2006-01-20 2009-05-12 Apotex Pharmachem Inc. Process for the preparation of 17-N-substituted-carbamoyl-4-aza-androst-1-en-3-ones
HU230730B1 (en) 2011-06-30 2017-12-28 Richter Gedeon Nyrt Process for the preparation of (5alpha,17beta)-n-[2,5-bis-(trifluoromethyl)-phenyl]-3-oxo-4-aza-5-androst-1-en-17-carboxylic amide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
NZ225100A (en) * 1987-06-29 1991-09-25 Merck & Co Inc Reaction of steroids (including 4-azasteroids) with a silylating agent in the presence of a quinone to introduce a delta' double bond and silylated intermediates

Similar Documents

Publication Publication Date Title
EP0428366B1 (en) Method for introducing a 1,2 double bond into azasteroids
HK1002708B (en) Method of introducing a 1,2 double bond into azasteroids
US4220775A (en) Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
EP0468012B1 (en) 17$g(b)-SUBSTITUTED-4-AZA-5$g(a)-ANDROSTAN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
EP0298652B1 (en) Dehydrogenation process and intermediates
US5091534A (en) Trialkylsilyl trifluoromethanesulfonate mediated α-methylenic carbon functionalization of 4-AZA-5α-androstan-3-one steroids
DE69313921T2 (en) New 7-beta-substituted-4-aza-5-alpha-cholestane-ons as inhibitors of 5-alpha-reductases
EP0307134B1 (en) Process for the preparation of methylene derivatives of androsta-1,4-diene 3-17 dione
US5091380A (en) N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
IE893483L (en) Methods of synthesizing benign prostatic hypertropic agents¹and their intermediates
US5196411A (en) 17β-acyl-3-carboxy-androsta-3,5-dienes as testosterone 5α-reductase inhibitors
DE69606623T2 (en) PHENYL-SUBSTITUTED 4-AZASTEROID FLUOR DERIVATIVES
US20040049042A1 (en) Process
US5075450A (en) Intermediates in the synthesis of 17β-acyl-3-carboxy-androsta-3,5-dienes
US5187278A (en) Trialkylsilyl trifluoromethanesulfonate mediated α-methylenic carbon functionalization of 4-aza-5α-androstan-3-one steroids
EP0478066A2 (en) New process for making 3-oxo-4-aza-androst-1-ene 17beta-ketones
CA2045865A1 (en) Intermediates on the synthesis of 17 beta-acyl-3-carboxy-androsta-3,5-dienes
EP0465142A1 (en) 17Beta-acyl-3-carboxy-androsta-3, 5-dienes as testosterone 5alpha-reductase inhibitors
EP0523688A1 (en) Process for the preparation of 17beta-substituted-4-aza-5alpha-androstan-3-one derivatives
US6187925B1 (en) Intermediates and process for the synthesis of azasteroids
Rama et al. A new convergent synthesis of WS-5995-B, an anticoccidial antibiotic from Streptomyces auranticolor
US5583228A (en) 17-halogeno-4-azaandrostene derivatives and process for the preparation thereof
CA2044905A1 (en) Selected 17 .beta.-polyaroyl-4-aza-5 .alpha.-androst-1-en-3-ones as steroidal reductase inhibitors
GB2273096A (en) Piperido(4',3':16,17)-4-aza-5 alpha-androstan-3-one derivatives and process for their preparation
HK1071376B (en) Methylene-4-azasteroids